Cancer-Myeloproliferative Neoplasms

Title: A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Description: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Drug/Procedure: Ruxolitinib; Anagrelide; Placebo
NCT Number: 03123588
Notes: Phase 2
Start Date: 10/24/17
Status: Recruiting
Principal Name: Kerry Pulver, MD
Contact Name: Olga Bittner, CCRC
Phone: (208)367-7954